Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
213Bi-DOTATOC
- Development stage
- Unknown
- Lead developer
- The University of New Mexico
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intra-arterial, Intravenous
01
Overview
213Bi-DOTATOC is an investigational somatostatin receptor-targeted alpha radiopharmaceutical comprising the somatostatin analogue edotreotide labeled with the alpha-emitting radionuclide bismuth-213. It binds primarily to somatostatin receptor subtype 2 on receptor-positive neuroendocrine tumor cells, is internalized, and delivers high-linear-energy-transfer alpha radiation that causes localized cytotoxic DNA damage. Preclinical rat pancreatic carcinoma studies showed dose-related antitumor activity, and first-in-human dose-escalation experience evaluated intra-arterial or systemic administration in patients with advanced neuroendocrine tumors refractory to beta-emitting DOTATOC therapy. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4525192/))
- Other names
- 213Bi-DOTATOCBi-213-DOTATOCBi213-DOTATOCBi 213-DOTATOCBi-TOC
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 213Bi-DOTATOC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 213Bi-DOTATOC.